Lesson learned in pediatric haploidentical transplantation in a low-resource environment: delivering melphalan IV and using low dose radiation reduce graft failure

References

• González-Llano O, González-López EE, Ramírez-Cázares AC, et al. Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in children and adolescents with hematological malignancies. Pediatr Blood Cancer. 2016 Nov 1;63(11):2033–2037.
   PubMed Web of Science ®Google Scholar
• Gale RP, Seber A, Bonfim C, et al. Haematopoietic cell transplants in Latin America. Vol. 51, Bone Marrow Transplantation. Nature Publishing Group; 2016; p. 898–905.
   Google Scholar
• Robinson TM, O’Donnell P V, Fuchs EJ, et al. Haploidentical bone marrow and stem cell transplantation: Experience with post-transplantation cyclophosphamide. Vol. 53, Seminars in Hematology. W.B. Saunders; 2016. p. 90–7.
   Google Scholar
• Schriber J, Agovi MA, Ho V, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant. 2010 Aug;16(8):1099–1106.
   PubMed Web of Science ®Google Scholar
• Al-Homsi AS, Roy TS, Cole K, et al. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Vol. 21, Biology of blood and marrow transplantation. Elsevier Inc.; 2015; p. 604–11.
   Google Scholar
• Ciurea SO, Cao K, Fernadez-Vina M, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Vol. 53, Bone marrow transplantation. Nature Publishing Group; 2018; p. 521–34.
   Google Scholar
• Ferrà C, Sanz J, Díaz-Pérez MA, et al. Outcome of graft failure after allogeneic stem cell transplant: Study of 89 patients. Leuk Lymphoma. 2015 Mar 1;56(3):656–662.
   PubMed Web of Science ®Google Scholar
• Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol [Internet]. 1997 Jun;97(4):855–864. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9217189.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1.
   PubMed Web of Science ®Google Scholar
• Fierro-Pineda JC, Tsai HL, Blackford A, et al. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023 Sep 26;7(18):5639–5648.
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Raffa E, Wall DA, et al. Outcome of haploidentical peripheral blood allografts using post-transplantation cyclophosphamide compared to matched sibling and unrelated donor bone marrow allografts in pediatric patients with hematologic malignancies: A single-center analysis. Transplant Cell Ther. 2022 Mar 1;28(3):158.e1–158.e9.
   PubMedGoogle Scholar
• Feng X, Wu Y, Zhang J, et al. Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: A meta-analysis. Vol. 20, BMC pediatrics. BioMed Central Ltd.; 2020.
   Google Scholar
• Jain T, Alahdab F, Firwana B, et al. Choosing a reduced-intensity conditioning regimen for allogeneic stem cell transplantation, fludarabine/busulfan versus fludarabine melphalan: A systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019 Apr 1;25(4):728–733.
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell P V, Symons HJ, et al. HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641–650.
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Cooke KR, Gamper CJ, et al. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematol. 2019 Apr 1;6(4):e183–e193.
   PubMed Web of Science ®Google Scholar
• Colunga-Pedraza PR, Gómez-De León A, Rodríguez-Roque CS, et al. Outpatient haploidentical stem cell transplantation using post-transplant cyclophosphamide is safe and feasible. Transplant Cell Ther. 2021 Mar 1;27(3):259.e1–259.e6.
   PubMedGoogle Scholar
• Lv M, Zhai SZ, Wang Y, et al. Class I and II human leukocyte antibodies in pediatric haploidentical allograft candidates: prevalence and risk factors. Bone Marrow Transplant. 2019 Aug 1;54(8):1287–1294.
   PubMed Web of Science ®Google Scholar
• Krummey SM, Gareau AJ. Donor specific HLA antibody in hematopoietic stem cell transplantation: Implications for donor selection. Vol. 13, Frontiers in immunology. Frontiers Media S.A.; 2022.
   Google Scholar
• Spellman S, Bray R, Rosen-Bronson S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010 Apr 1;115(13):2704–2708.
   PubMed Web of Science ®Google Scholar
• Mochizuki K, Sano H, Akaihata M, et al. T cell replete–haploidentical second hematopoietic stem cell transplantation for primary graft failure in pediatric patients with hematologic malignancies. Pediatr Transplant. 2017 Nov 1;21(7).
   PubMed Web of Science ®Google Scholar